Novel Cell-based treatment

ParkCell AB develops a novel potentially curative treatment for Parkinson’s disease, a common neurodegenerative disease.
ParkCell’s technology is a cell-based therapy aiming at re-establishing the lost functionality in the brain of Parkinson’s patients by utilizing transplantation of specialized autologous cells. This new cell-transplantation technology has promise to become a potent method for treating Parkinson’s disease.

.

Read more

Prediction of vulnerability

ParkCell also develops a novel biomarker-based diagnostic technology for early prediction of Parkinson’s disease long before patients start to display clinical symptoms. This novel diagnostic method has the potential to detect a possible endogenous vulnerability for development of the disease among close relatives.

.

.

Read more

Promising research

ParkCell’s technology is based on the principle of combining two different safe and well validated established medical treatments, and we have very encouraging data from conducted pre-clinical in vitro studies and in vivo investigations in Parkinson’s disease animal models. Today, ParkCell plans for clinical studies in humans, and in order to enter the clinical phase of development, we are open to discuss external funding and different collaboration models.
We also would like to encourage patients to support the development.

Read more